176 related articles for article (PubMed ID: 36641927)
21. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
[TBL] [Abstract][Full Text] [Related]
22. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Chang DY; Ma WL; Lu YS
Ther Clin Risk Manag; 2021; 17():193-207. PubMed ID: 33707948
[TBL] [Abstract][Full Text] [Related]
23. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells.
Krajnak S; Trier JP; Heinzmann PF; Anic K; Heimes AS; Loewe A; Schmidt M; Battista MJ; Hasenburg A; Brenner W
EXCLI J; 2023; 22():114-130. PubMed ID: 36998707
[TBL] [Abstract][Full Text] [Related]
25. Alpelisib in the treatment of metastatic HR+ breast cancer with
Mavratzas A; Marmé F
Future Oncol; 2021 Jan; 17(1):13-36. PubMed ID: 32964734
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of PI3K inhibitors in advanced breast cancer.
Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
Ann Oncol; 2019 Dec; 30(Suppl_10):x12-x20. PubMed ID: 31859349
[TBL] [Abstract][Full Text] [Related]
27. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
[TBL] [Abstract][Full Text] [Related]
28. The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.
Cataldo ML; De Placido P; Esposito D; Formisano L; Arpino G; Giuliano M; Bianco R; De Angelis C; Veneziani BM
Front Oncol; 2023; 13():1108242. PubMed ID: 37469415
[TBL] [Abstract][Full Text] [Related]
29. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
30. Periorbital edema associated with alpelisib.
Dao EA; George SJ; Heberton MM; Pacha O; Kovitz CA; Patel AB; Phillips RM
Cancer Treat Res Commun; 2022; 32():100596. PubMed ID: 35834907
[TBL] [Abstract][Full Text] [Related]
31. PI3K inhibition to overcome endocrine resistance in breast cancer.
Keegan NM; Gleeson JP; Hennessy BT; Morris PG
Expert Opin Investig Drugs; 2018 Jan; 27(1):1-15. PubMed ID: 29252036
[TBL] [Abstract][Full Text] [Related]
32. The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
Ladewig E; Michelini F; Jhaveri K; Castel P; Carmona J; Fairchild L; Zuniga AG; Arruabarrena-Aristorena A; Cocco E; Blawski R; Kittane S; Zhang Y; Sallaku M; Baldino L; Hristidis V; Chandarlapaty S; Abdel-Wahab O; Leslie C; Scaltriti M; Toska E
Cancer Res; 2022 Jun; 82(12):2269-2280. PubMed ID: 35442400
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
[TBL] [Abstract][Full Text] [Related]
34. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
[TBL] [Abstract][Full Text] [Related]
35. A multidisciplinary approach to optimizing care of patients treated with alpelisib.
Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA
Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012
[TBL] [Abstract][Full Text] [Related]
36. Alpelisib: A Novel Therapy for Patients With
Wilhoit T; Patrick JM; May MB
J Adv Pract Oncol; 2020; 11(7):768-775. PubMed ID: 33575071
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
[TBL] [Abstract][Full Text] [Related]
38. Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Toppmeyer DL; Press MF
Cancer Med; 2020 Sep; 9(18):6463-6472. PubMed ID: 32697890
[TBL] [Abstract][Full Text] [Related]
39. Alpelisib Efficacy without Cherry-PI3King Mutations.
Tau S; Miller TW
Clin Cancer Res; 2023 Mar; 29(6):989-990. PubMed ID: 36626159
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]